首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Idrugs

缩写:

ISSN:1369-7056

e-ISSN:

IF/分区:0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引2149
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
T J Torphy T J Torphy
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One highlight of the meeting was the disclosure of a new PDE isozyme, bringing to 11 the total number of genetically disti...
R M Orr R M Orr
This meeting covered a wide area of cancer research including the latest developments in drug discovery, new targets and translational research into the clinic. A flavor of this meeting is reported here.
J C Lovejoy J C Lovejoy
This meeting focused on the latest research and clinical developments in the field of obesity. Record high attendance emphasized the recognition of obesity as an emerging and exciting area of study, both from the basic science aspects as we...
B Rothschild B Rothschild
The 63rd National Scientific Meeting of the American College of Rheumatology was quite general in scope, with clinical and animal model studies forming the basis for this report. Arthritis-suppressive medications were further analyzed as to...
M Elisaf M Elisaf
This meeting primarily dealt with the assessment of global risk for the development of cardiovascular disease. There was also a discussion of the ongoing trials with hypolipidemic drugs, especially statins. Particular emphasis was given to ...
S P Ayalasomayajula,U B Kompella S P Ayalasomayajula
A symposium entitled 'Drug efflux pumps: challenges and opportunities' addressed the detection and functional characterization of drug efflux pumps, their influence on the cytochrome P450 (CYP450) system and their role in blood-brain barrie...
R Francis,D Chao R Francis
This meeting highlighted the exciting progress being made in biological therapies for cancer. There are now antibodies licensed for therapy, with cytokines available for therapy and growth factors in routine use. Understanding the immune sy...